STOCK TITAN

Leap Therapeutics, Inc. - LPTX STOCK NEWS

Welcome to our dedicated page for Leap Therapeutics news (Ticker: LPTX), a resource for investors and traders seeking the latest updates and insights on Leap Therapeutics stock.

Leap Therapeutics, Inc. (Nasdaq: LPTX) is a pioneering clinical-stage biopharmaceutical company focused on developing novel targeted antibody therapies for cancer treatment. Headquartered in Cambridge, Massachusetts, Leap Therapeutics aims to discover and advance transformative cancer treatments by targeting tumor-promoting pathways, cancer-specific cell surface molecules, and activating the immune system against cancer cells.

The company's lead program, DKN-01, is a humanized monoclonal antibody that targets Dickkopf-related protein 1 (DKK1). This promising candidate is in clinical trials for treating esophagogastric, gynecologic, and colorectal cancers. Another key program, FL-301, targets Claudin18.2-expressing cells and is being developed for gastric and pancreatic cancer treatments. Leap Therapeutics also has two preclinical antibody programs, FL-302 and FL-501, which are advancing toward developing innovative cancer therapies.

Operating as a single segment dedicated to oncology, Leap Therapeutics has established several strategic collaborations to enhance its development pipeline, including a clinical collaboration with BeiGene for the DisTinGuish trial and partnerships with NovaRock Biotherapeutics and Adimab. The company's dedication to advancing targeted and immuno-oncology therapeutics underscores its commitment to addressing unmet needs in cancer treatment. Leap's research and development activities continue to make significant progress, with ongoing clinical trials and new data demonstrating the potential efficacy and safety of its therapeutic candidates.

In recent news, Leap Therapeutics announced the completion of enrollment in the randomized controlled Part C of the DisTinGuish study, evaluating DKN-01 in combination with tislelizumab and chemotherapy for advanced gastroesophageal junction and gastric cancer. Additionally, the company reported financial results for the first quarter of 2024, highlighting a successful $40 million financing that extends its cash runway into the second quarter of 2026. This funding will support the expansion and continued execution of the DKN-01 development program, including the expansion of the randomized controlled Part B of the DeFianCe study in second-line colorectal cancer patients.

For more information about Leap Therapeutics, visit www.leaptx.com or view their public filings with the SEC available via EDGAR at www.sec.gov or www.investors.leaptx.com.

Rhea-AI Summary

Leap Therapeutics has completed enrollment of 188 patients in Part B of the DeFianCe study, evaluating DKN-01 for second-line treatment of advanced colorectal cancer (CRC). The study combines DKN-01, an anti-Dickkopf-1 antibody, with standard bevacizumab and chemotherapy. Dr. Cynthia Sirard, Chief Medical Officer, highlighted the enthusiasm for DKN-01's potential, citing encouraging data from Part A showing clinically meaningful response rates and durable tumor reductions.

The Phase 2, open-label, global study's primary endpoint is progression-free survival (PFS), with an additional focus on PFS in left-sided CRC patients. Secondary objectives include objective response rate, duration of response, and overall survival. Initial data from Part B is expected in mid 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.81%
Tags
none
-
Rhea-AI Summary

Leap Therapeutics (LPTX) reported Q2 2024 financial results, highlighting progress in its oncology pipeline. Key developments include:

1. Increased overall response rate (ORR) to 33% in the DeFianCe study for colorectal cancer.
2. Expanded Part B of DeFianCe study to 180 patients, with enrollment expected to complete by September 2024.
3. Ongoing patient follow-up in DisTinGuish study for gastroesophageal cancer, with data expected in Q4 2024 or early 2025.
4. Completed $40 million private placement with investors including Gilead Sciences.

Financial highlights: Net loss increased to $20.4 million, primarily due to higher R&D expenses of $17.9 million. Cash and cash equivalents stood at $78.5 million as of June 30, 2024, expected to fund operations into Q2 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Leap Therapeutics, Inc. reported financial results for Q1 2024, highlighting a $40 million private placement financing, completion of enrollment in key studies, and positive clinical data. The company's cash runway extends to Q2 2026, with plans for continued program expansion and major clinical milestones. Financially, net loss decreased to $13.8 million, research and development expenses dropped, and cash and cash equivalents stood at $54.9 million at the end of March 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
Rhea-AI Summary
Leap Therapeutics, Inc. announces a private placement of common stock and pre-funded warrants to raise approximately $40 million, extending cash runway into Q2 2026. The financing includes new and existing investors like Gilead Sciences, Inc. The proceeds will fund the expansion of the DKN-01 DeFianCe clinical trial and development program, supporting Leap's operations until Q2 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.47%
Tags
none
-
Rhea-AI Summary
Leap Therapeutics, Inc. (LPTX) reported financial results for Q4 and year-end 2023, highlighting new clinical data from Phase 2 studies on DKN-01 in colorectal and gastroesophageal cancers. The company showcased a 30% overall response rate and 93% disease control rate in CRC patients. Enrollment completion in the DisTinGuish study sets the stage for delivering randomized controlled data in 2024. Financially, the company reported a net loss of $81.4 million for 2023, with increased research and development expenses compared to 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
-
Rhea-AI Summary
Leap Therapeutics, Inc. (Nasdaq:LPTX) announced positive clinical data from the DeFianCe study, showing a 30% objective response rate (ORR) and 93% disease control rate (DCR) in second-line colorectal cancer (CRC) patients treated with DKN-01 plus bevacizumab and chemotherapy. The study revealed the greatest benefit in left-sided tumors, particularly rectal and rectosigmoid patients, with a 46% ORR, 100% DCR, and a preliminary median progression-free survival (PFS) of 9.4 months. The company plans to report additional clinical data and subgroup analyses in a conference call on January 23, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.61%
Tags
conferences clinical trial
Rhea-AI Summary
Leap Therapeutics, Inc. (Nasdaq:LPTX) to Present Corporate Overview at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.07%
Tags
conferences
-
Rhea-AI Summary
Leap Therapeutics, Inc. (Nasdaq:LPTX) completes enrollment in Part C of the DisTinGuish study evaluating DKN-01, their anti-Dickkopf-1 (DKK1) antibody, in combination with tislelizumab and chemotherapy for advanced gastroesophageal junction and gastric cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.67%
Tags
none
-
Rhea-AI Summary
Leap Therapeutics, Inc. (Nasdaq:LPTX) will present new data from the DeFianCe study at the 2024 ASCO Gastrointestinal Cancers Symposium, evaluating DKN-01, an anti-DKK1 antibody, in combination with bevacizumab and chemotherapy for advanced colorectal cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.28%
Tags
conferences
Rhea-AI Summary
Leap Therapeutics, Inc. (LPTX) President and CEO, Douglas E. Onsi, to participate in fireside chat at Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.87%
Tags
conferences

FAQ

What is the current stock price of Leap Therapeutics (LPTX)?

The current stock price of Leap Therapeutics (LPTX) is $3.24 as of November 8, 2024.

What is the market cap of Leap Therapeutics (LPTX)?

The market cap of Leap Therapeutics (LPTX) is approximately 131.3M.

What does Leap Therapeutics, Inc. specialize in?

Leap Therapeutics specializes in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells.

What is DKN-01?

DKN-01 is Leap Therapeutics' lead clinical candidate, a humanized monoclonal antibody targeting Dickkopf-related protein 1 (DKK1), being developed to treat esophagogastric, gynecologic, and colorectal cancers.

What are the latest developments in Leap Therapeutics' clinical trials?

Recent developments include the completion of enrollment in the Part C of the DisTinGuish study evaluating DKN-01 with tislelizumab and chemotherapy for advanced gastroesophageal junction and gastric cancer, and the expansion of the Part B of the DeFianCe study for second-line colorectal cancer.

Who are Leap Therapeutics' collaboration partners?

Leap Therapeutics collaborates with BeiGene for the DisTinGuish trial and has partnerships with NovaRock Biotherapeutics and Adimab.

What are the financial highlights from Leap Therapeutics' latest quarter?

For the first quarter of 2024, Leap Therapeutics reported a net loss of $13.8 million. Cash and cash equivalents totaled $54.9 million at the end of March 31, 2024. The company also completed a $40 million financing round in April 2024.

Where is Leap Therapeutics headquartered?

Leap Therapeutics is headquartered in Cambridge, Massachusetts.

What is FL-301?

FL-301 is one of Leap Therapeutics' clinical programs targeting Claudin18.2-expressing cells, being developed for gastric and pancreatic cancer treatments.

How does Leap Therapeutics plan to use the recent $40 million financing?

Leap Therapeutics intends to use the net proceeds to fund the continued development of its lead monoclonal antibody program, DKN-01, expand the randomized controlled Part B of the DeFianCe Study, enable data maturity in the Part C of the DisTinGuish study, and manufacture clinical trial material for Phase 3 readiness.

What are Leap Therapeutics' preclinical programs?

Leap Therapeutics has preclinical antibody programs, FL-302 and FL-501, which are aimed at developing new cancer treatments.

How can one access Leap Therapeutics' public filings?

Public filings can be accessed via EDGAR at the SEC's website (www.sec.gov) or through Leap Therapeutics' investor relations page (www.investors.leaptx.com).

Leap Therapeutics, Inc.

Nasdaq:LPTX

LPTX Rankings

LPTX Stock Data

131.34M
38.26M
17.31%
41.64%
1.89%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE